Video clip is available online.
VIDEO 1.
A video describing the unique aspects of this case report followed by the key findings from a review of all serotonin syndrome cases in the cardiology literature. Video available at: http://www.jtcvsonline.org/ article/S0022-5223(17)31103-0/addons. 
ACQ
The first night of the postoperative period, the patient became severely hypotensive despite vasopressor support. LVAD pump parameters were optimal, and no evidence of device malfunction was documented. Because of the copious blood products, vasopressors, inotropes, and crystalloids administered during LVAD placement, methylene blue (MB) was administered instead of fluids to increase systemic vascular resistance.
The subsequent morning, the patient was noted to be febrile and tachycardic with acute mental status change, repetitive horizontal eye movements, inducible sustained clonus, hypertonia, hyperreflexia in all extremities, and oral automatisms. Serotonin syndrome was suspected, and his medication list was reviewed for serotonergic agents. Notably, escitalopram 10 mg was taken daily before his hospitalization and substituted with citalopram 20 mg on admission 2 weeks previously. Serotonergic agents were withheld while alternative causes for his neurologic symptoms were investigated. A computed tomography scan showed no acute intracranial hemorrhage. An electroencephalogram showed no seizures or epileptiform discharges but did show an absent posterior background with continuous irregular diffuse delta/theta slowing consistent with severe encephalopathy. Bronchoalveolar lavage and urine cultures had no growth after several days. No overt abnormalities were seen on metabolic panels to account for his symptoms. He was treated with standing doses of lorazepam. After 2 days, his symptoms had notably improved. Within 1 week, his neurologic symptoms had fully resolved. He was discharged home 3 weeks later.
DISCUSSION
This article presents the first case of serotonin syndrome after a routine LVAD implantation and is the fourteenth case of serotonin syndrome in cardiology literature (Video 1). The 14 cases, along with their characteristics, etiology, symptomatology, treatment, and outcome, are presented 5HT, Serotonin; PO, per os (by mouth); QD, daily; MB, methylene blue; postop, postoperative; CABG, coronary artery bypass graft; IV, intravenously; QHS, every bedtime; BID, twice daily; LVAD, left ventricular assist device; ICU, intensive care unit. *Serotonergic agent; highly contraindicated in serotonin syndrome.
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in Table 1 . [1] [2] [3] [4] [5] [6] [7] [8] [9] All documented cases occurred within the last 9 years and 11 of 14 occurred within the last 2 years, which suggests a recent emergence in cardiology attributed to either increasing incidence, improving recognition, or both concurrently.
One common thread between all 14 cases is onset after fentanyl and/or MB administration. In the cardiac setting, fentanyl is used routinely for perioperative pain control and prevention of systemic increases in afterload. 10 Its role in serotonin syndrome is due to opioid-mediated release of serotonin in the central nervous system. 11 MB is used in emergency cases of vasoplegia, which is severe hypotension with low systemic vascular resistance and baseline or increased cardiac output. 12 Vasoplegia affects 8% to 24% of patients undergoing cardiac operations and has a mortality of 16% to 27%. 13 In patients with heart failure undergoing cardiac surgery, incidence is even greater: 27% in those with low ejection fraction and 42% in those undergoing LVAD placement.
14 MB has been shown to increase vascular tone and decrease vasoplegia duration and mortality in these situations. 13 It is a powerful inhibitor of vasodilation but generally is considered a ''last-resort'' treatment because of its adverse side effects and increased morbidity. 12, 15, 16 Serotonin syndrome is one of the concerns because of its ability to cross the blood-brain barrier and specifically inhibit the serotonin degrading enzyme monoamine oxidase A. 17 Other concerns are decreased renal and mesenteric blood flow, cardiac arrhythmias, and increased pulmonary artery pressure. 15, 16 The second common thread among 13 of 14 cases in Table 1 is antidepressant use before hospitalization. The most common antidepressants are selective-serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors, and tricyclics, which are all serotonergic agents. 18, 19 In Table 1 , 5 different SSRIs and one serotonin and norepinephrine reuptake inhibitor are represented across the 14 cases, indicating drug class is a more important precipitating factor than any one drug brand. This medication risk is relevant to cardiology because depression is an exceedingly common comorbidity of heart disease, particularly heart failure. 20, 21 In a study using the Beck Depression Inventory score, the authors found 35.3% (n ¼ 374) of patients with congestive heart failure had depression. 21 Similarly, a retrospective study of heart transplant patients found 38% were taking an SSRI at the time of surgery, 3 which indicates a substantial number of cardiology patients are at increased risk for serotonin syndrome. This deserves recognition when considering the use of serotonergic agents such as fentanyl or MB.
If fentanyl or MB cannot be avoided in a patient taking a serotonergic antidepressant, it is essential to remain vigilant for signs of serotonin syndrome. The Hunter Criteria, summarized in Table 2 , are used widely to identify clusters of symptoms that are highly sensitive (84%) and specific (97%) for serotonin syndrome. [22] [23] [24] It applies to cases in which a serotonergic agent was used within the last 5 weeks, although onset typically occurs within 24 hours of a medication or dose change. In this case report, the patient displayed inducible clonus, hypertonia, and pyrexia, which met criterion 4 in Table 2 . This diagnosis was reached with a high degree of certainty for multiple reasons: the Hunter Criteria has a specificity of 97% (low false positive rate), there is an appropriate close temporal relation between MB administration and symptom onset, and other common etiologies were excluded, such as intracranial hemorrhage, seizures, bacterial infection, and overt metabolic abnormalities. For these reasons, an exhaustive metabolic workup was not indicated.
In all cases of serotonin syndrome, the most important treatment is withdrawal of the causative agents. In mild cases, full neurologic recovery is expected within 24 to 72 hours with supportive care alone. 24 In moderate and severe cases, benzodiazepines should be used to reduce agitation. Cyproheptadine is a serotonin 2A receptor antagonist that is also advised, although its effectiveness in serotonin syndrome has not been definitively tested with randomized clinical trials. 25 Critically ill patients with muscle activity driving temperatures greater than 41.0 C require neuromuscular paralysis and intubation. Prognosis generally is favorable if serotonin syndrome is recognized and treated early.
CONCLUSIONS
Serotonin syndrome is a life-threatening condition that is emerging in cardiology. A comprehensive understanding of the condition, as presented in this article, is needed to address the emergence and maximize prevention while minimizing response time. If concomitant serotonergic agents such as SSRIs, fentanyl, and MB cannot be avoided, vigilance for signs of serotonin syndrome is key as it can be fully reversed with early recognition and treatment. 
